From: Therapy for metastatic melanoma: the past, present, and future
Trial | Patients | RR% (CR/PR) | PFS (months) | OS (years) | Number (patients) | Summary |
---|---|---|---|---|---|---|
Phase 3 Hodi et al. [24] | Ipilimumab plus gp100 versus Ipilimumab alone versus gp100 alone previously treated metastatic melanoma | 5.7 versus 10.9 versus 1.5 | 2.76 versus 2.86 versus 2.76 | 10.0 versus 10.1 versus 6.4 | 676 | Ipilimumab with significant improvement in OS versus gp-100. |
Phase 3 Robert et al. [23] | Ipilimumab plus dacarbazine versus dacarbazine in untreated metastatic melanoma | 15.2 versus 10.3 | Not stated | 11.2 versus 9.1 | 502 | Ipilimumab plus dacarbazine significantly with significant improvement in OS over dacarbazine. |
Phase 2 Hersh et al. [40] | Ipilimumab versus Ipilimumab plus dacarbazine in chemotherapy naïve patients with metastatic melanoma | 5.3 versus 14.3 | Not stated | 11.4 versus 14.4 | 72 | Ipilimumab plus dacarbazine improved RR and OS compared to single agent ipilimumab. |